Skip to main content
Neuropsychopharmacology logoLink to Neuropsychopharmacology
. 2017 Jul 13;42(9):1924. doi: 10.1038/npp.2017.92

A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder

Daniel Umbricht, Marta del Valle Rubido, Eric Hollander, James T McCracken, Frederick Shic, Lawrence Scahill, Jana Noeldeke, Lauren Boak, Omar Khwaja, Lisa Squassante, Christophe Grundschober, Heidemarie Kletzl, Paulo Fontoura
PMCID: PMC5520791  PMID: 28701745

Correction to: Neuropsychopharmacology advance online publication, 16 November 2016; doi:10.1038/npp.2016.232

In this paper, page 4: Table 1, Vineland II Adaptive Behavior score is a title; therefore the score ‘62 (12.9)’ should be removed. In the second paragraph of the RESULTS section, the VABS-II score should be ‘63 (12.5)’ instead of ‘62 (12.9)’. Page 6: Table 2, the WAVW (ratio) section, Eyes p-value should be ‘0.99,’ instead of ‘0.10’.


Articles from Neuropsychopharmacology are provided here courtesy of Nature Publishing Group

RESOURCES